CC
CERO

Centiva Capital’s CERo Therapeutics CERO Stock Holding History

Centiva Capital’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-135
Closed -$2.79M – 1897
2022
Q4 		$2.79M Buy
135
+114
+543% +$2.32M 0.08% 265
2022
Q3 		$425K Hold
21
– – 0.01% 927
2022
Q2 		$422K Buy
+21
New +$421K 0.01% 994

Other funds holding CERO

MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.67% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.83% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.58% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.82% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.01% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.28% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.21% 1-Year Est. Return

Centiva Capital's CERO Position: Q1 2023 in Review

Centiva Capital sold out of CERo Therapeutics (CERO) in Q1 2023, closing a stake of 135 shares — an estimated $2.79M sold.

Centiva Capital first reported a position in CERO in Q2 2022 and held it in 3 quarters. The position peaked at $2.79M in Q4 2022. 15 funds tracked by Wall St. Rank hold CERO as of Q1 2023.

  • Centiva Capital reported no remaining CERo Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Centiva Capital sold 135 CERo Therapeutics shares in Q1 2023, an estimated $2.79M.
  • Centiva Capital first reported a position in CERo Therapeutics in Q2 2022 and held it in 3 quarters.
  • Centiva Capital's CERo Therapeutics position peaked at $2.79M in Q4 2022.
  • 15 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2023.

Based on Centiva Capital's 13F filing for Q1 2023, filed 15 May 2023.